Australia limits use of AstraZeneca 19 vaccine to people over 60



SYDNEY/CANBERRA, June 17 (Reuters) - Australia will recommend only people over 60 receive AstraZeneca's AZN.L COVID-19 vaccine, the country's Minister for Health Greg Hunt said on Thursday, following a spate of blood clots in those who have received the inoculation.

Australia has administered 3.3 million doses of the AstraZeneca vaccine, and it has been linked to 60 cases of blood clots, the government has said. So far, two people have died, which Hunt said has driven the policy shift.

"The government places safety above all else," Hunt told reporters in Canberra.

"This updated advice received today is based on new evidence demonstrating a higher risk for the very rare (thrombocytopenia syndrome) condition in the 50-59 year-old age group."

Australia in April moved to limit the use of the AstraZeneca vaccine to people over 50 years old.

Several European Union member states have stopped administering the AstraZeneca vaccine to people below a certain age, usually ranging from 50 to 65, restricting its use to older people, due to very rare cases of blood clotting, mainly among young people.

Hunt said the recommendation would not delay its inoculation timetable, which has a target of giving at least one COVID-19 vaccine dose to every Australian before the end of 2021.

Australia in April expanded its order of Pfizer's PFE.N COVID-19 vaccine to 40 million doses, while it has also ordered 25 million shots from Moderna MRNA.O .

Australia's amended vaccine policy comes as the country's most populous state battles to contain a cluster of COVID-19 cases.

New South Wales said it now recorded four local cases of COVID-19, with the source of the outbreak still unclear.

"At this stage, we are all on high alert," NSW state Premier Gladys Berejiklian told reporters in Sydney.

A man in his 60s, who works as a driver for international airline crews, was detected with the virus on Wednesday, the state's first case in more than a month, and his wife has since tested positive. Genetic tests found the man has the Delta virus strain, officials said.

The Delta variant, which has been classified by the World Health Organisation (WHO) as among the four COVID-19 variants of concern due to evidence that they spread more easily, likely caused the latest devastating outbreak in India.

Nearly a dozen venues in Sydney including a cinema in a shopping centre in the popular tourist spot of Bondi and a supermarket have been listed as virus hotspots.

Australia has successfully suppressed past outbreaks through snap lockdowns, swift contact tracing and tough social distancing rules. It has reported just under 30,300 cases and 910 deaths since the pandemic began.
Reporting by Renju Jose in Sydney and Colin Packham in Canberra; Editing by Raju Gopalakrishnan

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.